1. U.S. Emerging Transdermal Drug Delivery Technologies Markets Limited Applications Curtail Market Expansion “Significant advancements in the transdermal delivery of proteins, peptides, and large molecules, promise great revenues. However, the commercialization of these products is still several years away.” Pharmaceutical Biotech Analyst Team Frost & Sullivan

2. Alternative routes of drug delivery continue to be developed and refined to enhance drug delivery and safety as well as patient convenience. Factors that have worked in favor of the transdermal drug delivery are its ease of use, sustained drug delivery, safety, and predictable efficacy. Years of research have furthered drug delivery development and many transdermal products are inching ahead through the clinical trials. The gel products, introduced in 2000 are expected to capture over one third of the total U.S. transdermal market by 2009. The introduction of active transdermal systems will strengthen the growth of the market during mid to later part of the forecast period. Industry Trends

3. Frost & Sullivan provides: Detailed insights into recent developments and trends Drivers, restraints, challenges, and strategic recommendations Analyst insights on ‘hot topics’ and emerging applications in the Transdermal Drug Delivery Technologies markets Market sizing and competitive analysis Market forecasts and opportunity analysis Quarterly assessments End user analysis within each report Key Features

4. Coverage: The United States Proven methodology encompassing extensive primary and secondary data and research Focused information and strategies that cover business and technology issues Credible data and analysis highlighting industry dynamics Winning strategies to help you create precise business plans What We Offer

5. Current Market Participants Find out how you compare to the competition Assess current and future drivers and restraints Determine and exploit new market share opportunities New Entrants Analyze challenges associated with the industry Calculate time scales for strategy implementation Position yourself to capitalize on the market’s unmet needs Investment Community Analyze long-term strategies of conferencing companies Determine which participants will outperform the competition Assess attractiveness of investing in teleconferencing market Who Will Benefit?

6. Passive Transdermal Patches Transdermal Gel Products Active Transdermal Products What’s Included

7. 3M Drug Delivery Systems Acrux Ltd. Adhesives Research, Inc. Altea Therapeutics Antares Pharma, Inc. AP Pharma, Inc. Auxilium Pharmaceuticals B. Braun Medical, Inc. Berlex Laboratories, Inc. BioSante Pharmaceuticals, Inc. Birch Point Medical, Inc. Cellegy Pharmaceuticals, Inc. Connetics Corp. Elan Drug Delivery Encapsulation Systems, Inc. Endo Pharmaceuticals Genetronics, Inc. Guilford Pharmaceuticals ImaRx Therapeutics, Inc. Iomed, Inc. Labtec Lohmann Therapy-Systems MacroChem Corp. Mylan Laboratories NexMed, Inc. Novavax, Inc. Noven Pharmaceuticals, Inc. Novosis AG Purdue Pharma L.P. Sano Corp. Sheffield Pharmaceuticals, Inc. Solvay Sontra Medical Corp. Transdermal Technologies, Inc. Transdermics Ltd. Vectura Ltd. Viragen, Inc. Vyteris, Inc. Watson Pharmaceuticals, Inc. West Pharmaceutical Services Women First HealthCare, Inc. Zars, Inc. Key Market Participants

8. Call toll free 877 G O F ROST (877.463.7876) Fax toll free 888.690.3329 E-mail myfrost@frost.com Visit www.frost.com For More Information